表皮生长因子受体相关靶向治疗与肺癌的研究进展.pdfVIP

• 56 • 中华胸部夕卜科电子杂志 2017 年 2 月第 4 卷第 1 期 ChinJThoracSurg(ElectronicEdition) ，Febrnary2017 ，Vol. 4 ，N o .l • 综 述 • 表皮生长因子受体相关靶向治疗与肺癌的 研究进展 王丹云1 彭忠民2 【摘要】 近年来, 非小细胞肺癌(NSCLC )的治疗进展主要以分子靶向治疗为主导地位。依据组织 和分子学类型制定个体化治疗方案已成为靶向治疗时代的准则，表皮生长因子受体(E G F R )基因是目 前肺癌众多驱动基因中研究最多、证据最充分、了解最透彻的一个分子靶点。表皮生长因子酪氨酸激酶 抑制剂(E G F R -T K I)已广泛应用于E G F R 突变的NSCLC 。该文将E G F R 相关靶向药物在N SCLC 的治 疗进展做一综述。 【关键词】 非小细胞肺癌； 肺腺癌； 表皮生长因子受体； 分子靶向治疗 Research progress of EGFR related targeted therapy and pulmonary carcinoma W ang Danyun1, Peng Zhongmin2. 1 Department o f General Thoracic Surgery, J inan Center H ospital a ff il ia t e d to Shandong University, Jin an 250013 ，China; 2D epartm ert o f General Thoracic Surgery, Shandong Provincial H ospital a ff il ia t e d to Shandong University, Jinan250021 ，China Corresponding author: Wang Danyun ，K m ail: yiyuanw dy@ sina. com 【Abstract 】 During the past several years， advances in the treatment of non-small cell lung cancer (NSCLC) have predominantly involved the development of therapies directed at molecular targets. Treatment based on histology andmolecular characterization has become a guideline of care in l^he era of targeted therapy. Among numerous driver genes of NSCLC ，epidermal growth factor receptor (EG FR ) gene is one molecular target concerning with most researches ，abundant evidences and thorough understandings. Epidermal growth factor tyrosine kinase inhibitor( EGFR-TKI) has been widely used in l^he treatment of NSCLC haboring EGFR mutation. This review provides an overview of current EGFR gene related targeted therapies in NSCLC. 【Key words】 Non-small cell lung cancer; Pulmonary adenocarcinoma ；Epidermll gro